Arvinas

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO

John G. Houston

CEOJohn G. Houston

Employees

445

Employees445

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2013

Founded2013

Employees

445

Employees445

ARVN Key Statistics

Market cap

2.24B

Market cap2.24B

Price-Earnings ratio

-5.05

Price-Earnings ratio-5.05

Dividend yield

—

Dividend yield—

Average volume

724.28K

Average volume724.28K

High today

$33.97

High today$33.97

Low today

$32.65

Low today$32.65

Open price

$33.80

Open price$33.80

Volume

415.37K

Volume415.37K

52 Week high

$53.08

52 Week high$53.08

52 Week low

$13.57

52 Week low$13.57

ARVN News

Yahoo Finance 2d

Arvinas to Present at Upcoming Investor Conferences - Yahoo Finance

Arvinas Inc. NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of dr...

Analyst ratings

90%

of 20 ratings

Buy

90%

Hold

10%

Sell